Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
详细信息 查看全文
- 作者：Willy Hugo1 ; 6 ; 9 ; Jesse M. Zaretsky2 ; 6 ; 9 ; Lu Sun1 ; 6 ; Chunying Song1 ; 6 ; Blanca Homet Moreno3 ; Siwen Hu-Lieskovan3 ; Beata Berent-Maoz3 ; Jia Pang3 ; Bartosz Chmielowski3 ; Grace Cherry3 ; Elizabeth Seja3 ; Shirley Lomeli1 ; 6 ; Xiangju Kong1 ; 6 ; Mark C. Kelley7 ; Jeffrey A. Sosman8 ; Douglas B. Johnson8 ; Antoni Ribas2 ; 3 ; 4 ; 5 ; 6 ; Roger S. Lo1 ; 2 ; 5 ; 6 ; rlo@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell
- 出版年：2016
- 出版时间：24 March 2016
- 年：2016
- 卷：165
- 期：1
- 页码：35-44
- 全文大小：2696 K
文摘
- •
High mutational loads may predict better survival, but not response to anti-PD-1
- •
BRCA2 mutations are enriched in melanomas responsive to anti-PD-1
- •
A transcriptional signature is related to innate anti-PD-1 resistance (IPRES)
- •
IPRES defines a transcriptomic subset across distinct types of advanced cancer